Spectaire (SPEC) Competitors $0.0003 0.00 (0.00%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock SPEC vs. THMO, HTGMQ, OLITW, PRENW, QSIAW, SMAPW, TT, KEYS, VLTO, and TERShould you be buying Spectaire stock or one of its competitors? The main competitors of Spectaire include ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), Keysight Technologies (KEYS), Veralto (VLTO), and Teradyne (TER). These companies are all part of the "measuring and control equipment" industry. Spectaire vs. Its Competitors ThermoGenesis HTG Molecular Diagnostics OmniLit Acquisition Prenetics Global Quantum-Si SportsMap Tech Acquisition Trane Technologies Keysight Technologies Veralto Teradyne Spectaire (NASDAQ:SPEC) and ThermoGenesis (NASDAQ:THMO) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation. Which has more volatility & risk, SPEC or THMO? Spectaire has a beta of -6.38, suggesting that its stock price is 738% less volatile than the S&P 500. Comparatively, ThermoGenesis has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Is SPEC or THMO more profitable? ThermoGenesis' return on equity of 0.00% beat Spectaire's return on equity.Company Net Margins Return on Equity Return on Assets SpectaireN/A -81.22% 304.57% ThermoGenesis N/A N/A N/A Does the media prefer SPEC or THMO? In the previous week, Spectaire's average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score. Company Overall Sentiment Spectaire Neutral ThermoGenesis Neutral Which has better valuation & earnings, SPEC or THMO? Spectaire has higher earnings, but lower revenue than ThermoGenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpectaireN/AN/A$8.95MN/AN/AThermoGenesis$9.61M0.00-$17.98M-$5.14N/A Do insiders and institutionals have more ownership in SPEC or THMO? 26.5% of Spectaire shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 25.4% of Spectaire shares are owned by insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryThermoGenesis beats Spectaire on 4 of the 7 factors compared between the two stocks. Get Spectaire News Delivered to You Automatically Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPEC vs. The Competition Export to ExcelMetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ ExchangeMarket Cap$6K$31.23M$29.97B$9.79BDividend YieldN/A8.22%3.06%4.02%P/E RatioN/A4.1256.1926.59Price / SalesN/A3.051,044.59155.79Price / CashN/A8.3835.9559.36Price / Book0.001.769.516.68Net Income$8.95M$7.16M$806.27M$265.59M7 Day PerformanceN/A-0.68%1.09%0.66%1 Month PerformanceN/A-7.19%2.04%2.64%1 Year PerformanceN/A-15.21%24,148.28%22.36% Spectaire Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPECSpectaireN/A$0.00flatN/AN/A$6KN/A0.008THMOThermoGenesisN/AN/AN/AN/A$1K$9.61M0.0040HTGMQHTG Molecular DiagnosticsN/AN/AN/AN/A$0.00$6.37M0.0090OLITWOmniLit AcquisitionN/A$0.08+7.3%N/A-45.5%$0.00N/A0.003Gap UpPRENWPrenetics GlobalN/A$0.02-12.9%N/A+164.4%$0.00$41.52M0.001Negative NewsGap DownQSIAWQuantum-SiN/A$0.40+2.6%N/A+350.0%$0.00$3.41M0.00150Positive NewsGap DownSMAPWSportsMap Tech AcquisitionN/A$0.03-4.1%N/A-26.5%$0.00N/A0.00N/AGap UpTTTrane Technologies4.245 of 5 stars$425.69-0.7%$458.60+7.7%+20.6%$95.41B$19.84B33.7645,000Positive NewsKEYSKeysight Technologies4.3918 of 5 stars$158.54-3.0%$187.38+18.2%+9.0%$28.14B$4.98B50.4915,500Positive NewsHigh Trading VolumeVLTOVeralto3.2913 of 5 stars$108.86+0.7%$113.43+4.2%-4.3%$26.83B$5.19B30.4117,000Positive NewsAnalyst ForecastTERTeradyne4.4468 of 5 stars$109.52-1.0%$114.44+4.5%-10.9%$17.60B$2.82B37.906,500Positive NewsDividend Announcement Related Companies and Tools Related Companies THMO Alternatives HTGMQ Alternatives OLITW Alternatives PRENW Alternatives QSIAW Alternatives SMAPW Alternatives TT Alternatives KEYS Alternatives VLTO Alternatives TER Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPEC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectaire Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectaire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access